Disorders of glucose metabolism in human immunodeficiency virus-infected patients.
Over the past 10 years, the development of highly active antiretroviral therapy (HAART) has dramatically improved morbidity and mortality in human immunodeficiency virus (HIV)-infected patients. Since the introduction of HAART however, unexpected metabolic abnormalities, including lipodystrophy, dyslipidaemia and dysregulation of glucose metabolism, are reported with increasing frequency in HIV-infected persons. Such metabolic disorders, if not treated, may be associated with an increased risk of cardiovascular disease in HIV-infected patients. In this paper, the prevalence, mechanisms and therapeutic strategies for the disorders of glucose metabolism in the context of HIV-infection are discussed.
Benhalima
K
K
Interne Geneeskunde, KU Leuven, Herestraat 49, 3000 Leuven, België.
Mathieu
C
C
Van Wijngaerden
E
E
D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D044882:Glucose Metabolism Disorders / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy*; D015658:HIV Infections / Q000150:complications* / Q000378:metabolism / Q000628:therapy; D006801:Humans
D044966:Anti-Retroviral Agents